Strategic partnerships Aridis has a history of collaboration with major organizations (IAVI, CF Foundation, Gates Foundation, AstraZeneca) and partners like TxBiomed, indicating openness to licensing, co-development, and funded programs that can be leveraged for joint ventures, technology licensing, or grant-backed initiatives.

Focused infectious disease With a clear focus on infectious diseases and an emphasis on inhaled formulations and delivery technologies, there are opportunities to position BD efforts around respiratory pathogens, vaccine adjuvants, and novel antibody therapies for high-need patient segments.

Funding readiness A track record of grants and investments from Gates Foundation and CF Foundation, plus ongoing interest from NPOs and philanthropic funders, suggests potential for targeted fundraising partnerships, milestone-driven programs, and grant-aligned pilots to de-risk early-stage collaborations.

Strategic licensing history Past licensing activity with AstraZeneca and a portfolio including monoclonal antibodies and nebulized formulations indicate a market-ready or near-market potential for licensing conversations, as well as opportunities to extend rights for adjuvanted vaccines or inhaled mAb platforms.

Small but nimble With a small team but high-impact focus, Aridis can be an attractive partner for fast-paced pilots, co-development sprints, or sponsored research initiatives that leverage its specialized inhalation technology without the overhead of large organizations.